COPD and Overweight, as a Problem in Present-Day Pulmonology
PDF

Keywords

chronic obstructive pulmonary disease
C-reactive protein
overweight

Abstract

Increasing incidence of chronic obstructive pulmonary disease (4th place among all causes of death within the general population) and overweight, as one factor for progression of respiratory tract pathologies (more than 30% of world population suffers from overweight) suggest that further study of pathogenetic peculiarities of their combined course and search for new ways of differential pathogenetic therapy are important nowadays.
https://doi.org/10.21802/gmj.2018.1.9
PDF

References

Bespalova ID, Riazantseva NV, Kaliuzhyn VV, et al. Systemic inflammation in the pathogenesis of metabolic syndrome and associated diseases . Syb Med J. 2013; 2:5-9.

Bychkova SA, Bychkova NH. Clinical and functional features of the course of chronic obstructive pulmonary disease combined with metabolic syndrome. Likarska sprava. 2014;7-8:54-59.

Vertkin AL, Skotnikov AS, Hubzhokova OM. Concomitant diseases in patients with chronic obstructive pulmonary disease: the role of chronic systemic inflammation and clinical pharmacological niches of roflumilast. Lechashchiy vrach. 2014 Feb;2:92-96.

Havrysiuk VK. Systemic manifestations of COPD: clinical features, diagnosis and treatment.Ukr Pulm J. 2009;2:7.

Hashynova EY. Systemic effects and comorbidity in outpatients with COPD. Ukr Pulm J. 2013; 2:41-45.

Hashynova KY. Influence of comorbid pathology on the frequency of hospitalizations when exacerbated by chronic obstructive pulmonary disease [Text]. Galician Medical Journal. 2014;21(3):15-18.

Hashynova KY. Influence of clinico-anamnestic and functional characteristics on the frequency of hospitalizations due to COPD exacerbation [Text]. Ukr Pulm J. 2014; 4:21-24.

Hriadil TI, Chubirko KI, Chopei IV, Hechko MM, et al. Diagnostics, treatment and prevention of overweight. Ukraine: Zdorovya natsiyi. 2015;1(33):96-100.

Dziublyk AY, Mukhin AA, Bialyk EI. Chronic obstructive pulmonary disease: contemporary pathogenesis concept, approaches to therapy. Clinical immunology alergology, infectiology. 2007;1:27-35.

Dziublyk AY. Exacerbation of COPD: modern treatment principles [Text]. Ukr Pulm J. 2011; 2:8-9.

Dziublyk AY. Virus-induced bronchial obstruction in patients with exacerbation of COPD: targeted action - good result. Zdoroviya Ukrayiny. 2012;2(18):16-17.

Dziublyk AY. Basic treatment of COPD: current trends and future perspectives. Zdorovia Ukrainy. 2011;7:42-43.

Dihtiar NI, Herasymenko ND, Savchenko LV et al. Systemic inflammation of low intensity as the general basis of chronic obstructive pulmonary disease and comorbid conditions. Ukr Pulm J. 2016; 3:64-68.

Brodskaya TA, Nezorova VA, Heltser BI, Motkina EV. Endothelial dysfunction and respiratory diseases.Ter archive. 2007;3:76-84.

Dudka PF, Dobrianskyi DV, Bychkova NH. Clinical aspects of disorders at the level of oppositional cytokines in patients with chronic obstructive pulmonary disease. Likarska sprava. 2009;5-6:27-31.

Ilnytskyy RI. Peculiarities of immunological reactivity in patients with chronic obstructive pulmonary disease. Ukr Pulm J. 2007; 2:21-24.

Karoli NA, Rebrov AP. Mortality in chronic obstructive pulmonary disease: the role of comorbidity [Text]. Clin Med. 2008; 3:18-20.

Kirsanova MP, Tovt-Korshynska MI, Zymokosova OV. Influence of metabolic therapy on the parameters of antioxidant homeostasis in patients with chronic obstructive pulmonary disease with concomitant arterial hypertension. Naukovyi visnyk Uzhhorodskoho universytetu. Medytsyna. 2010;39:76-79.

Kirsanova MP, Tovt-Korshynska MI, Briuzhina TS. Evaluation of fatty-acid profile in serum lipids and red blood cell membranes in patients with chronic obstructive pulmonary disease combined with arterial hypertension. Ukr Pulm J. 2011;2:52-54.

Karoli NA, Orlova EE, Markova AV, Rebrov AP. Comorbidity in chronic obstructive pulmonary disease. Ter archive. 2008;3:20-23.

Konopkina LI. Level of markers of systemic inflammation in patients with chronic obstructive pulmonary disease of severe course depending on their adherence to planned therapy. Problems of ecology and medicine. 2012:16(5-6):15-18.

Konopkina LI. Diagnostic significance of some markers of systemic inflammation in the infectious exacerbation of chronic obstructive pulmonary disease [Text]. Ukr Pulm J. 2012; 3:31-34.

Krakhmalova OO, Shtorkh VV, Hetman OA, et al. Chronic obstructive pulmonary disease and comorbid pathologies. Features of heart rhythm disorders. Ukr Ter J. 2016; 2:119-123.

Leshchenko IV. Main treatment options for chronic obstructive pulmonary disease. Therapeutic archive. 2007; 8:75-84.

Mostovy YM. Modern classifications and standards for the treatment of diseases of internal organs. Nevidkladni stany v terapiyi: Guide. 2013:51-63.

Mostovyy YM. Chronic obstructive pulmonary disease. Key issues. Ukr Med J. 2016; 4:63-66.

Ostrovsky MM, Arunkiv OI, Malofii LS, et al. New possibilities of influence on bronchoobstructive syndrome in cases of exacerbations of chronic obstructive pulmonary disease. Galician Medical Journal. 2011;18(14):116-121.160

Monogarova NY, Semendiaieva AV, Minaiev AA. Optimal choice of therapy for patients with COPD III-IV stages. Ukr Pulm J. 2010; 1:12-13.

Ostrovsky MM, Herych PR. On the issue of polymorbidity and comorbidity in patients with COPD [Text]. Ukr Pulm J. 2011; 4:19-24.

Ostrovsky MM. Modern opportunities and mistakes in the treatment of chronic obstructive pulmonary disease. Proceedings of the IV West Ukrainian scientific-practical conference, devoted to the problems of COPD. Zdorovia Ukrainy. 2010;10:12-3.152.

Pertseva TO, Sanina NA. The role of systemic inflammatory processes in the pathogenesis of chronic obstructive pulmonary disease [Text]. Ukr Pulm J. 2012; 4:48-50.

Pertseva TA, Hashynova YY. New peculiarities in the treatment of chronic obstructive pulmonary disease [Text]. Ukr Pulm J. 2010; 2:12-16.

Pertseva TA. COPD: modern issues. Ukr Pulm J.2010; 1:18-19.

Prystupa LN,Tsyhankova TI. Investigation of markers of inflammation in patients with chronic obstructive pulmonary disease. Visnyk Sum. Medytsyna. 2009;1:183-188.

On approval and implementation of medical-technological documents on standardization of medical care in chronic obstructive pulmonary disease: Order of the Ministry of Health of Ukraine No555 from June 27, 2013 [Text]. Ministry of Health of Ukraine. Official issue. Kyiv; 2007. 3p.

Rybas YH, Naryshkina SV. Contemporary ideas about anti-inflammatory therapy of chronic obstructive pulmonary disease. Bulletin of Physiological Pathology of Respiration.2013; 48:31-43.

Stupnytska HY, Fediv OI. Chronic obstructive pulmonary disease: Two sides of the same coin. UKr Ter J. 2013; 4:85-92.

Feshchenko YI, Chaikovsky YB, Ostrovsky MM, et al. Chronic obstructive pulmonary disease. New shades of the problem. Ivano-Frankivsk; 2016. 400p.

Feshchenko YI. Global strategy for diagnosis, treatment, prevention of COPD: What's new in 2013? [Text]. Zdoroviya Ukrainy. 2013;17 (318):45-46.

Feshchenko YI. Actual issues of chronic obstructive pulmonary disease. Ukr Pulm J. 2010; 1:6.

Feshchenko YI. Control over COPD - is it possible today? Zdorovia Ukrayiny. 2010 Dec;1 (13):10-11.

Chuchalin AH. Chronic obstructive pulmonary disease and concomitant diseases. Ter archive. 2008; 8:45-48.

Yashyna LA, Ishchuk SH. Excessive body weight, obesity and pathology of the lungs: a view of the pulmonologist. Zdoroviya Ukrayiny. 2011; 2(4):14.

Bahadori K, Fitzgerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation: systematic review [Text]. Int J. of COPD. 2007;2(3):241-251.

Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD [Text]. Eur Respir J. 2009;33:1165-1185. DOI: https://doi.org/10.1183/09031936.00128008 [PMid:19407051]

Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2: 367-370. DOI: https://doi.org/10.1513/pats.200504-026SR [PMid:16267364]

Agusti A, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122-125. DOI: https://doi.org/10.1186/1465-9921-11-122 [PMid:20831787 PMCid:PMC2944278]

Ambrossino N, Bruletti G. Cognitive and perceived health status in patients with chronic obstructive pulmonary disease surviving acute chronic respiratory failure: a controlled failure. Intensive Care Med.2002;28:170-177. DOI: https://doi.org/10.1007/s00134-001-1165-6 [PMid:11907660]

Vanfleteren LE et al. Body mass index and chronic airflow limitation in a worldwide population-based study [Text]. Chron Respir Dis. 2016;13(2):90-101. DOI: https://doi.org/10.1177/1479972315626012 [PMid:26768010 PMCid:PMC5734599]

Eddahibi S, Chaouat A, Tu L, et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;34:75-476. DOI: https://doi.org/10.1513/pats.200603-038MS

Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Updated 2017.

Moloney ED, Kiely JL, McNicholas WT. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease. Lancet. 2001;357:526-528. DOI: https://doi.org/10.1016/S0140-6736(00)04049-6

Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of "overspill" of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65:930-936. DOI: https://doi.org/10.1136/thx.2009.130260 [PMid:20627907]

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Downloads

Download data is not yet available.